Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) has provided an announcement.
On March 23, 2026, MaxCyte announced the appointment of Parmeet Ahuja as Chief Financial Officer and principal accounting officer, effective March 30, 2026, succeeding outgoing CFO Douglas Swirsky as part of a previously disclosed transition. Ahuja, 57, joins from Agilent Technologies, where he spent more than two decades in senior finance roles spanning investor relations, financial planning and analysis, operational finance, and global financial operations.
The hire brings seasoned public-market and life sciences finance expertise into MaxCyte at what management describes as a pivotal phase in the company’s growth, signaling an intent to strengthen its financial operations and investor-facing capabilities. Ahuja’s compensation package includes a $450,000 base salary, a target cash bonus equal to 50% of base pay, and substantial equity awards, along with a change-of-control and severance framework designed to provide continuity and stability in the finance function during potential strategic events.
The most recent analyst rating on (MXCT) stock is a Hold with a $150.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.
Spark’s Take on MXCT Stock
According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.
The score is held down primarily by weak financial performance (shrinking revenue, persistent losses, and ongoing cash burn) and bearish technical signals. Earnings-call positives (strong cash balance, reduced burn, and pipeline potential) help offset near-term guidance headwinds, while valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on MXCT stock, click here.
More about MaxCyte
MaxCyte, Inc. is a Nasdaq-listed cell-engineering company that provides enabling platform technologies to support the discovery, development and commercialization of next-generation cell therapies. Its offerings include Flow Electroporation technology and SeQure DX gene-editing risk assessment services, serving researchers and developers across the global cell and gene therapy industry.
The company focuses on precise, efficient and scalable cell engineering solutions, backed by scientific, technical and regulatory expertise to help partners advance safe and effective treatments. With more than 25 years in the field, MaxCyte positions itself as a key infrastructure player in the rapidly growing cell and gene therapy market, supporting both early-stage research and clinical translation.
Average Trading Volume: 1,097,694
Technical Sentiment Signal: Sell
Current Market Cap: $76.6M
See more data about MXCT stock on TipRanks’ Stock Analysis page.